Raju Mohan, the CEO AND PRESIDENT of $VTYX ($VTYX), bought 238,248 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...
Investors were unimpressed by the company's trial results for an ulcerative colitis therapy.
The company has several promising autoimmune therapies.
The biotech benefits from a much larger peer's recent FDA approval.
Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2...
ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company...
Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our selective NLRP3 inhibitor, VTX2735,...